Earnings Releases·Nov 6, 2026, 8:00 AM ET

Aligos Therapeutics — Third Quarter 2026 Earnings Summary

Net loss narrowed to $21.9 million ($2.09/share) for Q3 2026 from $31.5 million ($3.04/share) in the prior year, while nine-month losses widened to $46.4 million ($4.45/share) from $4.3 million ($0.44/share); total cash and investments declined to $31.1 million as of September 30, 2026, from $77.8 million at year-end 2025.
Revenue surged to $30.65 million for the nine months ended September 30, 2026, driven by $27.82 million in licensing revenue and $5.66 million in customer revenue, compared to $2.02 million in the prior period.
Cash on hand is projected to fund operations through Q1 2027, with top-line data for the Phase 2 B-SUPREME study of pevifoscorvir sodium expected in late Q3 2027.
The Phase 2 B-SUPREME study has completed enrollment, and the ASO candidate ALG-170675 has advanced into Phase 1 clinical studies in China funded by partner Amoytop.